Wallis C, Satkunasivam R, Butaney M, et al. - Because tumor mutational burden has been shown to be linked to response to immunotherapy (IO), researchers investigated whether smoking history is associated with a better response to IO. In patients with advanced solid organ malignancies, they used a systematic review with stratified meta-analysis of randomized clinical trials of IO vs standard of care. According to findings, smoking status is not significantly linked to the response to IO in the treatment of advanced solid organ malignancies. In addition, no significant difference was found between current and never smokers.